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Remotely Delivered Contraception With Needle-less 
Norgestomet Implants 
Darrel J. Kesler 
Abstract: A remotely delivered contraceptive was 
developed that suppressed estrus and prevented pregnancy 
in deer with 100-percent efficacy. This contraceptive utilized 
norgestomet, a potent progestin that is approved by the 
Food and Drug Administration (FDA) for use in cattle. 
Although the needle-less norgestomet implant is not FDA 
approved for use in deer, it is safe for treated animals, 
humans, and the environment. The remote delivery of this 
implant can be accomplished up to 40 m away and causes 
minimal tissue damage and stress if administered properly. 
Because of its ease, its simplicity of delivery, and the control 
it provides for proper drug handling, the needle-less 
norgestomet implant holds much promise for control of the 
overpopulation of deer in the United States. Further, no part 
of this product will remain to pollute the environment. 
Although this contraceptive was developed for female deer, 
preliminary studies suggest that the needle-less norgestomet 
implant may be effective in males. Widespread use of the 
needle-less norgestomet implant in deer requires further 
extensive (and costly) establishment of safety and efficacy 
as well as FDA approval. 
Kevwords: Remote deliverv, needle-less imDlants, 
norgestomet, norethindroneacetate, wildlife contraception, 
black-tailed deer, white-tailed deer, controlled release, 
silicone, Food and Drug Administration 
Introduction 
Deer overpopulation has become a major problem in Cost. The product has to be cost effective relative to 
many areas of the United States. Warren (1991) has other methods of population control. 
presented a detailed review of the historical causes of . Efficacy, The product has to be highly effective, 
this problem, the ecological effects of deer OverPoPu- 
~ l t h o u g h  ~oo-percent efficacy is not essential, like an 
lation, and the need for controlling deer populations. equivalent product for humans, it still must be highly 
Overpopulated deer herds are causing significant effective in  reve en ti no unwanted ~reanancies. 
economic losses in the form of crop damage, damage 
to landscape plantings, transmission of diseases to 
livestock such as cattle (Forbes and Tessaro 1993), 
and damage to vehicles and humans (injury or death) 
in deer-vehicle collisions. In many areas, regulated 
~ u b l i c  huntina has been Droven to be an effective 
~ ~~~ ~ 
., , " 
Ease of delivery. The product must be uncompli- 
cated and easy to deliver. Even if a product meets the 
previous three criteria with 100-percent efficacy, it will 
not be routinely used unless it can be delivered with 
simplicity and ease. 
u 
means of controlling deer populations (Behrend et al. Several contraceptive systems have been tested 
1970); however, this procedure has become very in deer and are reported in the literature. None of the 
controversial and political. Contraception of deer may, developed contraceptives, however, have been 
therefore, be a logical alternative to control deer accepted with enthusiasm either because of efficacy 
population. or because of the difficulty in their delivery. The 
. . 
The purpose of this article is not to provide an 
extensive review of the literature but rather to review a 
specific contraceptive (and its development) devel- 
oped for deer. Because this contraceptive utilizes a 
steroidal compound, I will refer to other steroids that 
have been tested for deer contraception, but I will not 
attempt to provide an extensive review of other 
contraceptive compounds or procedures. 
The selection of a deer contraceptive involves 
several criteria. The following is a selected list of 
essential criteria: 
Safety. This involves not only the animals being 
treated but also the human population and the envi- 
ronment. 
contraceptive most widely tested is the steroidal 
compound melengestrol acetate (MGAB; 17a-hydroxy- 
6-methyl-I 6-methylenepregna-4,6-diene-3,20- 
dione; fig. 1) (Budavari 1989, Bell and Peterle 1975, 
Matschke 1980, Plotka and Seal 1989). MGA is 
approved by FDA for use in cattle (0.5 mg is orally 
administered daily; Zimbelman and Smith [1966]) for 
the suppression of estrus, increased rate of weight 
gain, improved feed efficiency (Bennett 1993), and, 
more recently, estrus synchronization in the United 
States. Another steroid tested is levenorgesterel (also 
referred to as norgestrel; 13~thyI-17cc-ethynyl-17p- 
hydroxygon-4-en-hne; fig. 1) (Budavari 1989, Plotka 
and Seal 1989, White et al. 1994). Levenorgesterel is 
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Figure 1. Chemical structures of melengestrol acetate (top). 
levenorgesterel (middle), and norethindrone acetate (bottom) 
the active component of the Norplant@ implant ap- 
proved for human use as a contraceptive implant by 
FDA in the United States (McCauley and Geller 1992). 
Although effective, MGA requires the implanta- 
tion of a relatively large implant. These implants 
necessitate capturing the target animal and performing 
minor surgery for implantation (Plotka and Seal 1989). 
The implants have been demonstrated to be effica- 
cious for several breeding seasons (Matschke 1980). 
Levenorgesterel also requires animal restraint for 
implant placement; however, the implants are smaller 
than the MGA implants. Unexpectedly, both studies 
that used levenorgesterel in deer reported that- 
administered at dosages similar to those used effica- 
ciously in humans-levenorgesterel was not an 
effective contraceptive in deer (Plotka and Seal 1989, 
White et. al. 1994). 
Both MGA and levenorgesterel were delivered 
via silicone (polydimethylsiloxane) (Roseman 1972). 
Because controlled chronic release of steroids in vivo 
(which is necessary for steroidal contraception) is 
obtained with silicone implants, and because they are 
biocompatable in mammals (Dziuk and Cook 1966), 
silicone proves to be an efficacious delivery system 
suitable for steroidal compounds in deer (Kesler 
1989). 
Norethindrone Acetate (NA) 
The first compound selected for efficacy evaluation 
was norethindrone acetate (1 9-nor-1 7p-ethynyl- 
178-01-3-one acetate; fig. 1) (Budavari 1989). Its 
chemical structure is very similar to that of levenorges- 
terel. NA is used in combination with ethynylestradiol 
in the United States (with FDA approval) as an oral 
contraceptive in humans. A human contraceptive was 
selected because investigators originally assumed that 
it would be reasonable to obtain FDA approval (for use 
In deer) for a compound already approved for a 
human use. NA was also selected because (1) the 
acetate provides longer in vivo half-life (Sinkula 1978), 
and (2) esterification enhances steroid secretion from 
silicone implants (Christensen and Kesler 1984 and 
1986, Kesler et al. 1996). NA implants have been 
used efficaciously (as a contraceptive) in humans 
(McCauley and Geller 1992). The first, and last, study 
(as reported below) was in beef heifers; the compound 
norgestomet was then selected for evaluation as a 
deer contraceptive. 
Fourteen beef heifers were selected for the 
study. Heifers were divided into two groups. All 
heifers had been previously synchronized with prosta- 
glandin FZm (PGF2=; Kesler 1985a and b, Kesler and 
Favero 1989a) and observed for estrus. Twelve days 
after detected estrus, all heifers were bled, and 
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plasma was assayed by a validated enzyme-linked 
immunosorbent assay (ELISA) (Kesler et al. 1990) for 
progesterone concentrations. All 14 heifers had 
progesterone concentrations greater than 1.5 ngIrnL, 
which suggests that they had corpora lutea that 
developed subsequent to the previously detected 
estrus (Kesler et al. 1981). Half (7) of the heifers were 
subcutaneously implanted with an NA matrix silicone 
implant. The cylindrical implants, each 3.5 mm in 
diameter and 2.5 cm in length, were implanted 
subdermally on the convex surface of the ear. Each 
treated heifer received one implant that contained 
11.5 mg of NA (equivalent to 8.35 mg of norethin- 
drone). At the time of implant insertion, all heifers 
were administered a luteolytic dose of PGF,-. Im- 
plants were left in situ for 4 days; after removal, total 
remaining NA was determined (Kesler et al. 1995 and 
1 9 8 9 ~ ) .  In vitro implant secretion over 4 days was 
also determined and corrected for in vivo secretion by 
the procedure reported by Machado (1994). 
NA was released from the silicone implants in a 
typical linearly declining fashion (r = -0.997; y = 
x (-0.21) + 1.15) (Ferguson et al. 1988, Kesler and 
Favero 1989c, Kesler et al. 1995). Over the 4-day 
period, a total of 2.53 mg (22 percent of the total) was 
delivered in vivo. Three of the four control heifers 
(43 percent) were detected in estrus whereas all 
seven (100 percent) of the treated heifers were 
detected in estrus (table 1). 
Estrus was detected at similar times after PGFZm 
treatment for both groups. To verify PGF,=-induced 
luteolysis, all heifers were bled 2 days after PGF,u 
treatment, and plasma was assayed for progesterone 
concentrations (Kesler et al. 1990). The progesterone 
concentrations in all heifers suggested that luteolysis 
was ensuing or had ensued. 
In summary, NA did not suppress estrus. In fact, 
during a period of high NA secretion (2.53 mg over the 
4-day period), there was a tendency for more (P = 0.02) 
NA-treated heifers than control heifers to display 
estrus. Therefore, NA was not considered further. 
Table 1. Norethindrone acetate implant secretion and 
estrus supwression efficacy in beef heifers 
Item Control Treated 
Number 7 7 
Number in estrus 3 (43%) 7 (100%); 
Mean interval to estrus 61 hours 59 hours 
- -- 
~orethlndrone acetate secreted 
Day 1 0 947 Kg 
Day 2 0 738 ~g 
Day 3 0 501 kg 
Day 4 0 341 Kg 
Differed from the control group at the 0.02 level of significance 
Norgestomet Chemistry and 
Physiology 
Chemistry 
Norgestomet is approved by FDA for use in cattle for 
estrus synchronization (Darling 1993). The procedure, 
designated Syncro-Mate B8, includes a 9-day implant 
containing 6 mg of norgestomet and an intramuscular 
injection that consists of 3 mg of norgestomet and 
5 mg of estradiol valerate that is administered at the 
time of implant insertion (Chien 1978, Kesler et al. 
1995). The purpose of the implant is to suppress 
estrus. When it is used for estrus synchronization in 
cattle, subsequent timed breeding (cattle are bred 
48-52 hours after implant removal) pregnancy rates 
range from 40 percent to 60 percent (Odde 1990, 
Kesler and Favero 1996). Norgestomet has also been 
successfully used for resynchronization in cattle 
(Favero et al. 1993 and 1995, Machado 1994, Kesler 
et al. 1994) and for estrus suppression and synchroni- 
zation in sheep (Kesler and Favero 1989b and 1997). 
Chemically, norgestomet (1 7a-acetoxy-l l P- 
methyl-1 9-norpreg-4-ene-20,dione; SC 21 009) is a 
modified 19-norprogesterone (fig. 2). Norprogesterone 
is identical to progesterone except that the methyl 
group at the 19 position is absent. Norgestomet has 
two other modifications: the presence of a methyl 
group at the 11 position and an acetate at the 
17 position. Acetate has been added to provide longer 
half life in situ (Sinkula 1978). Norgestomet is me- 
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Figure 2. Chemical structures of progesterone (top) and 
norgestomet (bottom). Norgestomet is a norprogesterone (exactly 
likeprogesterone except the methyl group at the 19 posltion is 
absent). Two other differences from progesterone are that 
norgestomet has an acetate at the 17 position (in order to increase 
half-life in vivo), and a methyl group is included at the 11 position. 
tabolized quickly (Moffatt et al. 1993) and is excreted 
in the urine and feces (Searle 1982). In both urine 
and bile, most of the excreted metabolites are highly 
polar materials demonstrated to have only about 
4 percent of the progestational activity of norgestomet 
in the Clauberg assay (Searle 1982). 
Norgestomet is a highly biologically active 
progestin. Gilbert et al. (1974) demonstrated that 
norgestomet is 15 times more biologically active than 
progesterone when orally administered to rabbits and 
216 times more biologically active than progesterone 
when subcutaneously administered to estradiol-17P- 
treated mice. Wishart (1972) demonstrated that 
140 pg of norgestomet and 45 mg of progesterone 
were required to suppress estrus in all treated heifers 
(which means that norgestomet is 321 times more 
potent than progesterone in this model). These data, 
combined with the data of Zimbelman and Smith 
(1966), would suggest that MGA is 90 times more 
potent than progesterone. This minimal dose of 
norgestomet required to suppress estrus in cattle was 
confirmed with silicone implant delivery of norgesto- 
met by Machado (1994) and Machado and Kesler 
(1996). In their studies, 6-mg and 8-mg silicone 
implants were administered to cows for 16 days. 
None of the cows with 8-mg implants were detected in 
estrus with implants in situ. The smallest daily dose of 
norgestomet released by these implants was 136 pg, 
which occurred on day 16. However, in three cows 
with 6-mg implants, estrus was detected the first day 
after implant secretion dropped below 136 pglday. 
Although this represents only 16 percent of the treated 
cows, 100-percent efficacy of estrus suppression was 
lost. 
Norgestomet's principal mode of action for estrus 
synchronization is by suppressing estrus. Further, 
norgestomet has the progesterone biological activity to 
maintain pregnancy in ovariectomized heifers (Favero 
et al. 1990; Kesler, in press). Favero and coworkers 
demonstrated that norgestomet would maintain 
pregnancy from day 10 through parturition. Upon 
removal of the norgestomet implants, parturition (if the 
implants were removed at term) or abortion (if the 
implants were removed at midgestation or earlier) 
occurred within 52 hours. Therefore, norgestomet is 
as effective as progesterone (but at a substantially 
reduced dosage) for two of progesterone's main 
biological actions: estrus suppression and pregnancy 
maintenance. 
Progesterone also has a role in regulating 
luteinizing hormone (LH) and subsequent follicular 
growth and maturation. Experiments utilizing the 
commercial hydron (polyethylene glycomethacrylate; 
Short 1975) norgestomet implant (6 mg) have demon- 
strated that, when it was implanted during pro-estrus, 
the dominant follicle present was maintained for the 
duration of the treatment, and there was no growth of 
medium or small follicles (Rajamahendran and Taylor 
1991). Systemic estradiol concentrations were also 
elevated, and there was insufficient progestin activity 
to maintain a strong negative feedback on LH pulse 
frequency in a manner comparable to that of the luteal 
phase of a normal estrous cycle (Savio et al. 1993). 
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Rajamahendran and Taylor (1991) suggested that this 
implied that the norgestomet treatment given during 
pro-estrus mimics the actions of low concentrations of 
progesterone. This time period is, in fact, a time of 
low norgestomet secretion by the hydron implant 
(Kesler et al. 1995), and, therefore, obtaining a low 
progestin effect would be expected. In fact, when 
implants were changed during the persistence of the 
dominant follicle, LH pulse frequency decreased, 
estradiol concentrations decreased, and follicular 
atresia occurred (Savio et al. 1993). Therefore, when 
given in appropriate amounts, norgestomet was 
effective in provoking the progestinlike negative 
feedback on LH pulse frequency and on follicular 
atresia. 
These conclusions were supported by Butcher et 
al. (1992), who reported that daily injections of 100 mg 
were was required to elevate systemic progesterone 
concentrations to levels of the luteal phase 
(5 to 7 ng1mL). In contrast, daily injections of only 
45 mg were required to suppress estrus in all treated 
animals (Wishart 1972). The dosage selected for the 
norgestomet implant was based on the minimal 
quantity required to suppress estrus. 
Administration of norgestomet on days 5-21 of 
the estrous cycle had no effect on progesterone 
secretion by corpora lutea (Domatob et al. 1994) and 
no negative effects on the establishment of pregnancy 
(Favero et al. 1993 and 1995, Machado 1994, Kesler 
et al. 1994). In order to assess the effect of 
norgestomet on early corpora lutea function and 
development in bovines, norgestomet was adminis- 
tered on days I ,  2, 3, and 4 after estrus (2 cowsiday). 
The implants were left in situ for 12 days. In all eight 
cows, development of the corpora lutea, secretion of 
progesterone, and length of the estrous cycle were 
unaffected by norgestomet treatment. Therefore, 
negative feedback of norgestomet during met-estrus 
and di-estrus did not disrupt corpora lutea develop- 
ment or function (Kesler, unpubl. data). 
It has been reported that norgestomet has a 
higher binding affinity to bovine uterine receptors than 
progesterone (Moffatt et al. 1993). Interestingly, 
however, although norgestomet has a higher binding 
affinity to bovine receptors, it did not bind (less than 
0.1-percent cross-reactivity) to highly specific anti- 
progesterone immunoglobulin G developed in rabbits 
(Kesler et al. 1990). Norgestomet exhibits only a 
weak ability to competitively bind bovine endometrial 
glucocorticoid receptors (Moffatt et al. 1993). Although 
norgestomet does not interact with endometrial 
estrogen receptors, it exhibits weak estrogenic activity 
when tested in an estrogen-dependent stimulation of 
human breast cell test. However, to provoke estrogen 
stimulation, a dose of at least 100 mg of norgestomet 
given at one time would be required (Moffatt et al. 
1993). 
Norgestomet Safety 
To obtain FDA approval for its use in cattle, investiga- 
tors conducted numerous studies to establish 
norgestomet's safety in both the treated animals 
(cattle) and humans (Searle 1982). For cattle, studies 
were conducted with doses up to 60-fold excess to the 
recommended dose (6 mg implants). Daily observa- 
tion of animals indicated no adverse reactions. Fur- 
ther, postmortem evaluation of the thoracic and 
abdominal viscera indicated that norgestomet caused 
no adverse effects. 
To evaluate human safety, researchers con- 
ducted several studies in both monkeys and rats 
(Searle 1982). The study conducted in monkeys was 
designed to evaluate the human oral contraceptive 
effect of norgestomet. Oral treatment of 30 and 
100 pglkg (but not 0 and 10 lgikg) per day increased 
the length of menstrual cycles, decreased the ovula- 
tion rate, and decreased the number of cycles during 
the 84-day treatment period. Throughout the treat- 
ment period, the only remarkable effect was amenor- 
rhea, which was observed in five of six and three of 
six monkeys orally administered daily doses of 30 or 
100 pglkg, respectively. Further, when norgestomet 
was administered at these doses, the conception rate 
was depressed to zero. The 10 pgikg of norgestomet 
per day had no significant effects on menstrual cycle 
length, ovulation rate, amenorrhea, or conception rate 
(Searle 1982). 
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For the rat studies, norgestomet was adminis- 
tered orally by gavage to two generations of rats at 
daily doses of 0, 0.0001, 0.001, 0.01,0.1, or 1.0 mgikg 
(Searle 1982). Administration of all doses produced 
no clinical signs indicative of toxicity. Weight gain was 
affected slightly only in the second-generation rats 
treated at the 1.0 mglkg daily dosage. Also, in these 
same second-generation rats, fertility was slightly 
lower when compared to that of controls. There were 
no gross or histologic (adrenals, pituitary, and sex 
organs) changes that could be attributed to treatment 
with norgestomet. Absolute and relative organ 
weights from the treated groups were not different 
from the controls, although there was a slight decrease 
in liver weights in all treated animals. 
In published resynchronization studies where 
norgestomet was administered during pregnancy, 158 
pregnancies have resulted (Favero et al. 1993 and 
1995, Machado 1994, Kesler et al. 1994, Domatob et 
al. 1997). No adverse effect of any kind has been 
observed. Therefore, the administration of norges- 
tomet does not appear to affect embryonic or fetal 
development. However, as previously noted, 
norgestomet will inhibit parturition and therefore 
should not be inadvertently administered to pregnant 
animals where the implant is not going to be removed 
before parturition (Favero et al. 1990; Kesler, in press). 
Contraceptive Efficacy 
One study of norgestomet's contraceptive efficacy in 
deer was completed in 1995 (Jacobsen et al. 1995), 
and another was more recently published (DeNicola et 
al. 1997). Jacobsen's study was conducted in con- 
fined black-tailed deer. This study included 10 deer of 
which 7 were treated with 42-mg norgestomet implants 
approximately 1 month before the breeding season. 
In addition to the 10 female deer, 2 fertile males were 
included in the same confined area. Observations 
were collected over a 2-year period after treatment. 
Subsequent to treatment, all of the treated 
female deer failed to exhibit estrous behavior. Further, 
males exhibited neither intentional pursuit, courting, 
nor tending bond behaviors toward treated females. 
After the first breeding season, all three control deer 
fawned, producing two sets of twins and one set of 
triplets. None of the seven treated deer fawned. All of 
the 10 female deer exhibited estrous behavior the next 
breeding season, and all 10 conceived. 
Although this study utilized a small sample, 
additional studies with white-tailed deer (DeNicola et 
al. 1997) confirm the contraceptive effect of the 42-mg 
norgestomet implant. In addition, a contraceptive 
effect with similar efficacy to that of the 42-mg implant 
has been demonstrated with a 21-mg norgestomet 
implant (DeNicola et al. 1997). 
The desired duration of contraception is contro- 
versial. Some groups encourage lifetime sterilization; 
others suggest that contraceptives should be revers- 
ible. The needle-less norgestomet implant was 
designed, as data confirmed, to be a 1 -year contra- 
ceptive. Therefore, after 1 year of reducing the deer 
population, a decision can be made regarding how to 
control it in subsequent years. 
Release from the 42-mg implant has been 
evaluated. This was accomplished by utilizing a 
validated in vitro system that mimics in vivo secretion 
(Kesler et al. 1995). Implants were evaluated daily 
over a 4-month period. The release of norgestomet 
from the implants was in a typical linear declining 
fashion (see figs. 3 and 4; Kesler et al. 1995). The 
best fit line was determined by correlating daily 
norgestomet released v. the log of day in vitro. This 
produced a correlation coefficient of -0.996. The 
maximal release of 638 pg was on the first day. 
During the first 3 months, more than 136 pg of 
norgestomet was released daily. This is a quantity 
that, as described earlier, suppresses estrus in cattle. 
The amount of norgestomet released daily thereafter 
decreased linearly. Based on the best fit release, 
norgestomet was released from the implant for 
252 days. 
For practical reasons, emphasis was placed on 
developing a contraceptive for the female deer. 
However, the contraceptive effects of progestins in 
males have been known for some time (Liskin and 
Quillin 1983). To assess the usefulness of 
norgestomet in male animals, researchers conducted 
a preliminary study to evaluate its effects on fertility- 
related factors in male rats. 
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This study included six males rats that were 
12 weeks old at the onset of the experiment. Three 
rats served as controls and received no treatment. 
The other three rats were each administered one 6-mg 
silicone implant. At the end of 9 days, the implants 
were removed and replaced with new 6-mg silicone 
implants. This cycle continued for 63 days (7 im- 
plantslrat-9 dayslimplant). On day 63, all six rats 
were killed and trunk blood was collected. The 
plasma was analyzed for testosterone concentrations 
via a validated ELlSA (Kesler et al. 1990). In addition, 
testes were collected and weighed. Mean individual 
testis weight of the norgestomet-treated rats was 
reduced (P< 0.01) and was only 37 percent of the 
control rats' mean testis weight (table 2). Mean 
testosterone concentrations in the plasma of 
norgestomet-treated rats were only 15 percent of the 
control rats'testosterone concentration. Although not 
Table 2. Mean testosterone concentrations and testes 
weights of rats treated with norgestomet. 
Item Control Treated 
Number 
-. . 
3 
-~ .~. 
3 
Mean individual 
testis weight 2.08 g 0.76 g' 
Mean testosterone 
concentrations 4.54 ng/mL 0.66 ng/mLZ 
Offers from the control group at the 0.01 level of significance. 
Differs from the control group at the 0.19 level of signifcance. 
highly significant (P= 0.19), norgestomet clearly had a 
biological effect on testosterone concentrations. A 
high level of significance (P<  0.05) was not achieved 
because the untreated rats demonstrated significant 
variability in their testosterone concentration and 
because so few animals were included in this prelimi- 
0- 
0 14 28 42 56 70 84 98 112 
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0- 
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Figure 3. Actual daily in vitro release of norgestomet. Daily 
observations were collected; however, only weekly observations 
are illustrated. 
Figure 4. Daily release (with days converted to log of days) in vitro 
of norgestomet Daily observations were collected; however. only 
weekly observations are illustrated. The regression equation IS Y = 
X (-265.26) + 637.23 with Y = norgestomet concentration [pg] and 
X =log of days (r = 0 .996;  P < 0.01). 
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nary study. However, the three norgestomet-treated 
rats had the three lowest concentrations of testoster- 
one in their plasma. 
Collectively, these data suggest that norgestomet 
may have a contraceptive effect in males. However, 
these studies were conducted with high concentra- 
tions of norgestomet and not in deer. Further investi- 
gations evaluating sperm concentrations in the 
epididymis of male deer or in their ejaculate are 
needed. 
Remote Needle-Less Delivery 
Delivery of contraceptives to free-roaming animals is 
critical to successfully suppressing reproduction. The 
idea contraceptive should (1) be capable of being 
delivered remotely, (2) not pollute the environment, 
and (3) allow control such that only animals intended 
to be treated are treated and that the drug is handled 
and dispensed properly. 
The norgestomet implants used in the deer 
efficacy studies were needle-less implants (fig. 5) that 
could be delivered at distances up to 40 m from the 
target animal (DeNicola et al. 1996). The needle-less 
implants have two major components. Their outer 
shell is manufactured from food-grade biodegradable 
and biocompatable chemicals. The components are 
already approved as food additives; even if all of the 
implant remained in place at the time of slaughter and 
was eaten by humans, that would not pose a hazard 
(U.S. Government 1993). The outer biodegradable 
shell is 0.635 cm in diameter and 2 cm long. The 
second component is the norgestomet manufactured 
in a matrix silicone implant. The silicone matrix is 
0.42 cm in diameter and 1.4 cm long. It weighs 21 5 mg, 
of which 42 mg (19.5 percent) is norgestomet. The 
outer shell combined with the siliconelnorgestomet 
weighs about 880 mg. 
The needle-less implants are propelled via a 
compressed-air delivery system. For the 1995 study 
(Jacobsen et al. 1995), the needle-less implants were 
delivered at 26,152 cmlsecond (858 feetlsecond) 
producing 3.07 x l o 5  g-cm (22.15 foot-pounds) of 
Figure 5. The needle-less norgestomet implant used in the deer 
studies. The photo shows the outer biodegradable shell (0.635 cm 
in dlameter and 2 cm long) and the inner silicone matrix 
norgestomet implant (0.42 cm in diameter and 1.4 cm long). 
kinetic energy. This system was designed for use in 
cattle, whose skin is far thicker than that of deer 
(Kesler and Favero 1997). Propelling the implants with 
that much kinetic energy caused trauma in deer 
(Jacobsen et al. 1995). 
Jacobsen's coworkers administered the needle- 
less implants in biceps femoris or semitendinosus or 
semimembranosus muscular at a distance of 3-30 m. 
Upon contact, deer exhibited one of two reactions: 
fleeing response without any apparent change in gait, 
followed by standing and grooming of the administra- 
tion site, or immediate carriage of the hindlimb and 
lack of attempted weight bearing for variable dura- 
tions. 
In subsequent studies, the needle-less implant 
has been delivered with far less kinetic energy. Using 
less kinetic energy does not compromise the accuracy 
but significantly reduces the trauma in deer (DeNicola 
et al. 1997). In fact, when needle-less implants can 
be delivered silently, deer have minimal reaction to 
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their delivery. In one study where cortisol concentra- 
tions were monitored to evaluate stress caused by the 
needle-less implant, they were not increased (Kesler, 
unpubl. data). 
Upon contact with the skin, the needle-less 
implant first causes it to stretch (Gould 1984). After 
stretching, the implant penetrates the skin by produ- 
cing a slit in it. After penetration has occurred, the 
skin then contracts back to almost its original form, 
with only a small slit left behind. The entry slit is 
shorter than the diameter of the projectile. Minimal, if 
any, bleeding occurs after penetration. Scab forma- 
tion follows (Willis et al. 1994, DeNicola et al. 1996). 
The projectile does not carry a portion of the animal's 
hide into the wound but leaves behind only a small, 
raised welt on the skin at the point of projectile entry 
(Drake and Paul 1976, Kesler et al. 1989a). 
Upon entry into living tissue, the outer shell 
dissolves in vivo in approximately 6 hours. I con- 
ducted both in vitro and in vivo studies to determine 
dissolution of the outer shell (table 3). The matrix 
silicone implant, although biocompatable and nonirri- 
tating, remains and delivers norgestomet by Fick's first 
law of diffusion as long as there is norgestomet 
contained within the silicone. By design, two deer that 
have been remotely treated with needle-less 
norgestomet implants were killed (about 2 months 
after treatment), and investigators examined the 
administration sites and musculature. In both cases, 
the norgestomet-silicone implant was recovered. 
Surrounding tissue was normal (DeNicola et al. 1996). 
This remote delivery system is unique and has 
many advantages over all other delivery formats. 
Another remote delivery system utilizes syringe darts. 
Although syringe darts provide remote delivery, a 
nondegradable syringe and needle remain in the 
environment. Another remote delivery system being 
proposed utilizes genetically engineered viruses which 
provides no or very minimal control on its spread 
(Morell 1993, Wagner et al. 1994). 
Table 3. In vitro and in  vivo dissolution of the 
biodegradable shell of the needle-less norgestomet 
implant 
Hour Percent of implant dissolved 
5 98 '98.25 
'6.39 100 - 
- 
' In vitro condtions conssted of suspending the implant shell in 100 mL of 
phosphate buttered salne (pH 7.0) at 37 'C. 
I . .O .,n I ' i , r  i :,I . <:eo :. .l. .~a'lco., , r1uilrlt '9 "IC .. : ant :-r r 
,,!,,,I. k 5 ,.<,,'4 .,3:3 ?.I.%, mQ3v2' :?  >"Vt ..,CO'S '?., :?:,'?< 
n r l r .  271: Z E I - ' ~  ? ? . ~ ~ a m o . r ~ o r  irr,.?'%r: . : r a n r J  
N o  observatons were collected lor tmes marked - 
'At 5 hours after mpantation. approxmately 2 percent. 0 percent, 3 percent. 
and 2 percent of the implant was rernanng. 
The implant shell had completely dssolved at 6.08, 6 42, and 6.67 hours 
after placing the mplants n solution 
iAt 24 hours after ~mplantaton, no intact implants were present in any of the 
four treated rabbits. 
Government Regulations 
It is not the purpose of this article to review govern- 
ment regulations; however, it is important to make a 
few important comments. First and foremost, the 
norgestomet-silicone contraceptive reported herein is 
not approved for use by FDA. An Investigational New 
Animal Drug (INAD) authorization has to be granted to 
conduct the experiments reported. FDA has required 
that these studies be conducted only on confined 
animals and that they do not escape in such a way 
that they could enter the human food chain. Although 
approved in cattle, norgestomet is not approved for 
widespread use in deer. Before that approval is 
possible, a sponsor much accomplish numerous tasks 
(table 4) to ensure that the product is efficacious and 
safe not only to the treated animals but also to the 
humans that may consume treated animals. It is my 
opinion that this product can be approved by FDA. 
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Table 4. Information required to be submitted to the 
FDA's Center for Veterinary Medicine when requesting 
approval for the marketing of a new animal drug 
product (Center for Veterinary Medicine 1994) 
1 ldent~flcatlon 
- 
2 Table of Contents and Summary 
I Chemiqtrv . . 
11 Sc~entlflc rat~onale and purpose 
3. Labeilng 
i. Label identification 
ii. Nonprescription labeling 
iii. Prescription labeling 
iv. Use restrictions 
v. Medicated feed labellng 
vi. Draft labeling 
4. Components and Composition 
i. Components 
ii. Composition 
iii. Fermentation of drua substance 
5. Manufacturing Methods. Facilities, and Controls 
I. Manufacturer 
i .  Personnel 
iii. Facilitieslequipment 
iv. New drug substance synthesis 
v. Raw material control 
vi. Manufacturing instructions 
vii. Analytical controls 
viii. Lot control number 
xi. Container 
x. Stability 
xi. Additional procedures 
xii. GMP (good manufacturing practice) compliance 
- ~ - 
6. Samples 
7 Analyt~cal Methods for Res~dues 
8 Ev~dence to establ~sh safety and effectlveness 
9 Good Laboratory Practlce Compliance 
10 Environmental Assessment 
11 Freedom of lnformatlon Summary 
12 Confident~al~ty of Data and lniormatlon In a New An~mal Drug 
Appllcatlon 
However, requirements for distribution have yet to be 
accomplished. 
Since animals treated with norgestomet would 
have their implant in situ during the hunting season, a 
legitimate concern is finding the answer to the ques- 
tion, what will happen to the people who consume 
such an implant in a treated animal? First, tissue 
studies demonstrate that minimal norgestomet residue 
exists in all treated cattle tissues except liver and 
kidney (Searle 1982). Second, in regard to consump- 
tion of an implant, the silicone is exceptionally durable. 
When placed in vitro in concentrated hydrochioric acid 
over a 3-day period, the polymer is unaffected. There- 
fore, complete breakdown and absorption of all 
remaining norgestomet (like the effect on compressed 
pellets) is extremely unlikely (or impossible). Further, 
implants incubated in 250 mL of 1 N hydrochloric acid 
(at 37 "C), to mimic the acidic conditions of the 
stomach, released the same amount of norgestomet 
as in plasma in vitro conditions. New implants incu- 
bated for 24 hours in plasma and 1 N hydrochioric 
acid released 638 pg and 648 pg, respectively (within 
1.5 percent of each other). Therefore, consumption of 
an implant a few weeks after implantation would 
release less than the safe 10 pglkg daily dose previ- 
ously discussed in monkeys. 
Summary 
Progesterone, produced by the corpus luteum, sup- 
presses estrus in deer and cattle. Synthetic 
progestins (melengestrol acetate and norgestomet) 
that suppress estrus in cattle are also effective in deer. 
Synthetic progestins that are effective contraceptives 
in humans, however, do not suppress estrus and are 
not effective contraceptives in deer or cattle. Steroidal 
compounds are often viewed negatively because of 
the diethyistilbestrol (DES) scenario, even though they 
are widely used by humans. DES became implicated 
as a carcinogen because large doses (50 mglday) of 
DES given to pregnant women caused an increased 
incidence of cervical cancer in their daughters (0.14 to 
1.4 cases per thousand exposures [Cheeke 19931). 
Norgestomet evokes all progesteronelike actions but 
at a much reduced dosage. Further, there are no data 
available to indicate that this steroid poses a risk. In 
addition to the data reported herein, norgestomet has 
been used for over a decade in cattle without any 
reported problems to either the cattle or to the human 
consumption of meat from treated animals. The only 
known progestin potent enough to be manufactured in 
a remotely delivered needle-less implant and still be 
efficacious as a contraceptive is norgestomet. This 
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contraceptive system was evaluated by a scientific 
committee for use in wild goats (Warren 1992). That 
committee gave the needle-less norgestomet the 
highest possible ratings for delivery, safety, and 
efficacy. All data support their conclusions. In fact, 
the committee rated the needle-less norgestomet 
implant as the best contraceptive for wild goats 
(Warren 1992). Based on all data available, the same 
conclusion can be reached for deer. I encourage 
further evaluation and support of the development of 
this contraceptive for use in deer. 
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